✦ LIBER ✦

Prevention of Cardiovascular Complications of Diabetes Mellitus by Aspirin

✍ Scribed by Nobles-James, Candi ;James, Erskine A. ;Sowers, James R.

Book ID: 109106122
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 101 KB
Volume: 22
Category: Article
ISSN: 0897-5957
DOI: 10.1111/j.1527-3466.2004.tb00142.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Aspirin therapy and primary prevention o

Aspirin therapy and primary prevention of cardiovascular disease in diabetes mellitus

✍ Naveed Younis; Steve Williams; Handrean Soran 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

Epidemiology of cardiovascular complicat

Epidemiology of cardiovascular complications in type 2 diabetes mellitus

✍ J.B. Meigs 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 40 KB

Cardiovascular complications of diabetes

✍ S. Caprio; S. Wong; K. G. M. M. Alberti; G. King 📂 Article 📅 1997 🏛 Springer 🌐 English ⚖ 66 KB

Reducing the cardiovascular consequences

Reducing the cardiovascular consequences of diabetes mellitus

✍ Philippe Passa 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB 👁 2 views

Type 2 diabetes is an important, independent risk factor for cardiovascular disease. As a result of the pandemic explosion of Type 2 diabetes, reducing the human and financial consequences of the disease is a major healthcare concern. In primary prevention, antihypertensive treatment, aspirin and li

Outcome of pregnancies complicated by pr

Outcome of pregnancies complicated by pre-gestational diabetes mellitus

✍ J E. Gunton; A McElduff; M Sulway; J Stiel; I Kelso; S Boyce; G Fulcher; B Robin 📂 Article 📅 2000 🏛 Wiley (Blackwell Publishing) 🌐 English ⚖ 675 KB

Prevention of insulin-dependent diabetes

Prevention of insulin-dependent diabetes mellitus 1998

✍ Pozzilli, Paolo 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 3 views

Recent advances in the understanding of the pathogenesis of insulin-dependent diabetes mellitus (IDDM) have led to the first trials of disease prevention in susceptible individuals. Two main trials (nicotinamide and insulin) are now running but first results will not be available before the turn of